What Can-Fite BioPharma Ltd.’s Phase 2b pancreatic cancer strategy reveals about immunotherapy combination economics

Can-Fite BioPharma Ltd. advances Namodenoson into Phase 2b pancreatic cancer testing. Discover what this means for immunotherapy economics.